GlassScriptPhysician profile
James B Craven
NPI 1659365104
$7,665.47
in general payments reported to CMS, 2019-2025
37 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,103 · 2021: $803 · 2022: $849 · 2023: $920 · 2024: $1,204 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $913.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $901.22 | 2019-2025 | Farxiga, Wainua |
| Amarin Pharma, INC. | $655.07 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $598.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $545.13 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $529.46 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $458.53 | 2019-2025 | Avvigo Guidance System, Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.82 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $342.52 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $324.47 | 2021-2025 | Verquvo |
| Abiomed | $296.28 | 2021-2025 | Impella |
| Janssen Pharmaceuticals, INC | $180.14 | 2020-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $179.10 | 2019-2024 | |
| Philips North America LLC | $163.00 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Chiesi USA, INC. | $162.94 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $138.50 | 2023-2024 | Inpefa |
| Shockwave Medical, INC | $129.93 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $112.48 | 2021-2024 | Confirm Rx, Diamondback Coronary, Assurity |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Medtronic, INC. | $74.45 | 2021-2024 | Azure Xt Dr Mri Surescan, Corevalve Evolut R |
| Alnylam Pharmaceuticals INC. | $51.75 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $31.87 | 2022-2023 | Nexletol |
| Altathera Pharmaceuticals LLC | $30.28 | 2025 | Sotalol Hydrochloride |
| Irhythm Technologies, INC. | $29.90 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $29.32 | 2023-2024 | |
| Daiichi Sankyo INC. | $28.56 | 2025 | Injectafer |
| Edwards Lifesciences Corporation | $24.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.48 | 2019-2020 | |
| Cardiva Medical, INC. | $22.30 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Regeneron Healthcare Solutions, INC. | $21.74 | 2019 | |
| Inari Medical, INC. | $21.04 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kiniksa Pharmaceuticals International, Plc | $19.64 | 2024 | Arcalyst |
| Bard Peripheral Vascular, INC. | $19.27 | 2023 | Rotarexs 6 F X 135 Cm |
| Asahi Intecc USA, INC. | $16.30 | 2025 | Asahi Coronary Wires |
| Cardiovascular Systems INC. | $15.45 | 2020 | |
| Medtronic Vascular, INC. | $14.72 | 2019 | |
| Elutia, INC. | $3.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Craven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.